Expression of tyrosine hydroxylase in an immortalized human fetal astrocyte cell line; in vitro characterization and engraftment into the rodent striatum.
The use of primary human fetal tissue in the treatment of neurodegenerative disorders, while promising, faces several difficult technical and ethical issues. An alternative approach that would obviate these problems would be to use immortalized cell lines of human fetal central nervous system origin. An immortalized human fetal astrocyte cell line (SVG) has been established (45) and herein we describe the in vitro and in vivo characteristics of this cell line which suggest that it may be a useful vehicle for neural transplantation. The SVG cell line is vimentin, GFAP, Thy 1.1 and MHC class I positive, and negative for neurofilament and neuron specific enolase, consistent with its glial origin. To determine whether the cell line could be used as a drug delivery system, a cDNA expression vector for tyrosine hydroxylase was constructed (phTH/Neo) and stably expressed in the SVG cells for over 18 months as demonstrated by immunohistochemistry and Western blotting of the stable transfectants. HPLC analysis of the supernatant from these cells, termed SVG-TH, consistently found 4-6 pmol/ml/min of l-dopa produced with the addition of BH4 to the media. Furthermore, in cocultivation experiments with hNT neurons, PC-12 cells and primary rat fetal mesencephalic tissue, both the SVG and SVG-TH cells demonstrated neurotrophic potential, suggesting that they constituitively express factors with neuroregenerative potential. To determine the viability of these cells in vivo, SVG-TH cells were grafted into the striatum of Sprague-Dawley rats and followed over time. A panel of antibodies was used to unequivocally differentiate the engrafted cells from the host parenchyma, including antibodies to: SV40 large T antigen (expressed in the SVG-TH cells), human and rat MHC class 1, vimentin, GFAP, and tyrosine hydroxylase. While the graft was easily identified with the first week, over the course of a four week period of time the engrafted cells decreased in number. Concomittantly, rat CD4 and CD8 expression in the vicinity of the graft increased, consistent with xenograft rejection. When the SVG-TH cells were grafted to the lesioned striatum of a 6-hydroxydopamine lesioned rats, rotational behavior of the rat decreased as much as 80% initially, then slowly returned to baseline over the next four weeks, parallelling graft rejection. Thus, the SVG-TH cells can induce a functional recovery in an animal model of Parkinson's disease, however as a xenograft, the SVG cells are recognized by the immune system.
Tornatore
C
C
Molecular Therapeutics Section, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Baker-Cairns
B
B
Yadid
G
G
Hamilton
R
R
Meyers
K
K
Atwood
W
W
Cummins
A
A
Tanner
V
V
Major
E
E
D000818:Animals; D001253:Astrocytes / Q000201:enzymology / Q000637:transplantation* / Q000648:ultrastructure; D002455:Cell Division / Q000502:physiology; D002460:Cell Line / Q000166:cytology / Q000201:enzymology / Q000648:ultrastructure; D048429:Cell Size / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D004195:Disease Models, Animal; D016332:Fetal Tissue Transplantation; D005333:Fetus / Q000166:cytology / Q000201:enzymology; D005434:Flow Cytometry; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology; D005818:Genetic Engineering; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008854:Microscopy, Electron; D017072:Neostriatum; D016501:Neurites / Q000502:physiology; D016627:Oxidopamine / Q000494:pharmacology; D016716:PC12 Cells / Q000166:cytology; D010302:Parkinson Disease, Secondary / Q000628:therapy; D010957:Plasmids; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D016042:Transplantation, Heterotopic; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics / Q000378:metabolism*
D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase